Literature DB >> 3283258

Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population.

D Cohen1, M S Green, C Block, T Rouach, I Ofek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3283258     DOI： 10.1093/infdis/157.5.1068

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  65 in total

1.  Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.

Authors:  V Pozsgay; C Chu; L Pannell; J Wolfe; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

Review 4.  Progress and pitfalls in Shigella vaccine research.

Authors:  Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein; Alessio Fasano; Karen L Kotloff; Myron M Levine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-19       Impact factor: 46.802

5.  An update on vaccines against Shigella.

Authors:  Shai Ashkenazi; Dani Cohen
Journal:  Ther Adv Vaccines       Date:  2013-09

6.  Evaluation of a conjugate vaccine platform against enterotoxigenic Escherichia coli (ETEC), Campylobacter jejuni and Shigella.

Authors:  Renee M Laird; Zuchao Ma; Nelum Dorabawila; Brittany Pequegnat; Eman Omari; Yang Liu; Alexander C Maue; Steven T Poole; Milton Maciel; Kavyashree Satish; Christina L Gariepy; Nina M Schumack; Annette L McVeigh; Frédéric Poly; Cheryl P Ewing; Michael G Prouty; Mario A Monteiro; Stephen J Savarino; Patricia Guerry
Journal:  Vaccine       Date:  2018-09-27       Impact factor: 3.641

7.  Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Authors:  D Cohen; S Ashkenazi; M Green; Y Lerman; R Slepon; G Robin; N Orr; D N Taylor; J C Sadoff; C Chu; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

8.  Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Authors:  A B Hartman; C J Powell; C L Schultz; E V Oaks; K H Eckels
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.

Authors:  Yehuda Chowers; Joachim Kirschner; Nathan Keller; Iris Barshack; Simon Bar-Meir; Shai Ashkenazi; Rachel Schneerson; John Robbins; Justen H Passwell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

10.  Shigella flexneri transformants expressing type 1 (mannose-specific) fimbriae bind to, activate, and are killed by phagocytic cells.

Authors:  A Gbarah; D Mirelman; P J Sansonetti; R Verdon; W Bernhard; N Sharon
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.